Efficacy of adenine arabinoside 5'-monophosphate in kidney recipients with chronic active hepatitis B: a pilot study. 1993

S Pol, and C Saltiel, and C Legendre, and F Carnot, and F Driss, and P Berthelot, and C Bréchot, and C Ruet, and H Kreis
Service de Transplantation Rénale, Hôpital Necker, Paris, France.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection

Related Publications

S Pol, and C Saltiel, and C Legendre, and F Carnot, and F Driss, and P Berthelot, and C Bréchot, and C Ruet, and H Kreis
March 1985, Gastroenterology,
S Pol, and C Saltiel, and C Legendre, and F Carnot, and F Driss, and P Berthelot, and C Bréchot, and C Ruet, and H Kreis
January 1982, Hepatology (Baltimore, Md.),
S Pol, and C Saltiel, and C Legendre, and F Carnot, and F Driss, and P Berthelot, and C Bréchot, and C Ruet, and H Kreis
January 1986, Journal of hepatology,
S Pol, and C Saltiel, and C Legendre, and F Carnot, and F Driss, and P Berthelot, and C Bréchot, and C Ruet, and H Kreis
March 1988, Annals of internal medicine,
S Pol, and C Saltiel, and C Legendre, and F Carnot, and F Driss, and P Berthelot, and C Bréchot, and C Ruet, and H Kreis
September 1989, Hepatology (Baltimore, Md.),
S Pol, and C Saltiel, and C Legendre, and F Carnot, and F Driss, and P Berthelot, and C Bréchot, and C Ruet, and H Kreis
March 1995, Gut,
S Pol, and C Saltiel, and C Legendre, and F Carnot, and F Driss, and P Berthelot, and C Bréchot, and C Ruet, and H Kreis
January 1986, Journal of hepatology,
S Pol, and C Saltiel, and C Legendre, and F Carnot, and F Driss, and P Berthelot, and C Bréchot, and C Ruet, and H Kreis
July 1985, Gut,
S Pol, and C Saltiel, and C Legendre, and F Carnot, and F Driss, and P Berthelot, and C Bréchot, and C Ruet, and H Kreis
January 1984, Gastroenterology,
S Pol, and C Saltiel, and C Legendre, and F Carnot, and F Driss, and P Berthelot, and C Bréchot, and C Ruet, and H Kreis
January 1986, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!